SIGNIFICANCE OF THE DYNAMICS OF THE LEVEL OF A SERUM LIVER FIBROSIS MARKER WFA + -M2BP IN PATIENTS WITH CHRONIC HEPATITIS B
Keywords:
chronic hepatitis В, liver cirrhosis of HВV etiology, biomarker, WFA -M2BP, liver fibrosis, antiviral therapyAbstract
Objective. To determine the role of the dynamics of the level of serum marker of liver fibrosis WFA+-M2BP in patients with chronic hepatitis В.. 56 patients with chronic hepatitis В who received antiviral therapy were examined. The degree of liver fibrosis was determined by indirect elastometry. Patients with the degree of liver fibrosis F0 were 8 people, F1 – 17 people, F2 - 6 people, F3 - 12 people and F4 - 13 people. The level of WFA+-M2BP was determined before the appointment of antiviral therapy, 6 month and 12 months. It was shown that both in patients with chronic hepatitis В and in patients with cirrhosis of the liver, a decrease in the levels of serum marker WFA+-M2BP in the dynamics of antiviral therapy is noted. The average value of WFA+-M2BP with liver fibrosis F3 (p<0,01) and F4 (p<0,01) was significantly higher than with the degree of fibrosis F0. In chronic hepatitis В with an increase in the degree of liver fibrosis, there is an increase in WFA+-M2BP levels and a decrease in the value of this biomarker in the dynamics of antiviral treatment. The determination of the dynamics of the level of this biomarker will allow timely detection of early degrees of liver fibrosis and monitoring of fibrosis in patients receiving antiviral therapy.
References
WHO. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/hepatitis-в.
WHO Global hepatitis report, 2017.
Atsushi Kuno, Yuzuru Ikehara, Yasuhito Tanaka, Kiyoaki Ito, Atsushi Matsuda, Satoru Sekiya, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Scientific Reports. 2013 Volume 3, Article number: 1065.
Ura K, Furusyo N, Ogawa E, Hayashi T, Mukae H, Shimizu M, et al. Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C. Aliment Pharmacol Ther. 2016 Jan;43(1):114-124. DOI: 10.1111/apt.13431.
Koji Fujita, Noriyuki Kuroda, Asahiro Morishita, Kyoko Oura, Tomoko Tadokoro, Takako Nomura, et al. Fibrosis staging using direct serum biomarkers is influenced by hepatitis activity grading in hepatitis C virus infection. J. Clin. Med. 2018 Sep;7(9):267. DOI: 10.3390/jcm7090267.
Ching-I Huang, Chung-Feng Huang, Ming-Lun Yeh, Yi-Hung Lin,
Po-Cheng Liang, Meng-Hsuan Hseih, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients. Kaohsiung Journal of Medical Sciences. 2017 Aug;33(8):394-399.
Zou X, Zhu M, Yu DM, Li W, Zhang DH, Lu FJ, et al. Serum WFA+ -M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection. Liver Int. 2017 Jan;37(1):35-44. DOI: 10.1111/liv.13188.
Ishida H, Suetsugu A, Nakamura M, Tauchi R, Nakayama J, Katano Y, et al. Change in Serum Levels of New Hepatic Fibrosis Marker "Mac-2 Binding Protein Glycosylation isomer (M2BPGi)" in Patients with Chronic Hepatitis C during the Treatment of Pegylated Interferon and Ribavirin. Rinsho Byori. 2015 Aug;63(8):901-906.
Ming-Yu Zhu, Pei-Zhan Chen, Jing Li, De-Min Yu, Dao Huang, Xue-Juan Zhu, et al. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients. J.Med.Virol. 2018 Apr;90(4):721–729. DOI:10.1002/jmv.25010.
Lung-Yi Mak, Danny Ka-Ho Wong, Ka-Shing Cheung, Wai-Kay Seto, Ching-Lung Lai and Man-Fung Yuen. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clinical and Translational Gastroenterology. 2018 Jun;9(6):163. DOI: 10.1038/s41424-018-0020-9.
EASL: Clinical Practice Guidelines: Management of hepatitis С virus infection. Journal of Hepatjlogy. 2014 Feb;60(2):392–420. DOI: 10.1016/j.jhep.2013.11.003.
Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Korenaga M, et al. Serum WFA+ -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int. 2015;36: 293–301.
Kazumi Yamasaki, Masakuni Tateyama, Seigo Abiru, Atsumasa Komori, Shinya Nagaoka, et al. Elevated Serum Levels of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein Predict the Development of Hepatocellular Carcinoma in Hepatitis C Patients. Hepatology. 2014 Nov;60(5):1563-70. doi: 10.1002/hep.27305. Epub 2014 Oct 2.
Inoue T, Tsuzuki Y, Iio E, Shinkai N, Matsunami K, Fujiwara K, et al. Clinical Evaluation of Hepatocarcinogenesis and Outcome Using a Novel Glycobiomarker Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA+-M2BP) in Chronic Hepatitis C with Advanced Fibrosis. Jpn. J. Infect. Dis. 2018 May;24;71(3):177-183. DOI: 10.7883/yoken.JJID.2017.459.
Tomi Jun, Yao-Chun Hsu, Shintaro Ogawa, Yen-Tsung Huang, Ming-Lun Yeh, Cheng-Hao Tseng, et al. Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection. Hepatology. 2014;60(5):1563–70.
Nagata H, Nakagawa M, Nishimura-Sakurai Y, Asano Y, Tsunoda T, Miyoshi M, et al. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. Hepatol Int. 2016 Nov;10(6):956-964. Epub 2016 Jul 19.
